Chemokine News and Research RSS Feed - Chemokine News and Research

Chemokines are a family of small cytokines, or proteins secreted by cells. Proteins are classified as chemokines according to shared structural characteristics such as small size (they are all approximately 8-10 kilodaltons in size), and the presence of four cysteine residues in conserved locations that are key to forming their 3-dimensional shape.
Research finding could lead to development of effective vaccines against microbial infections

Research finding could lead to development of effective vaccines against microbial infections

The diverse functions of a special cell-recognition lipoprotein, LOX-1, weren't always fully understood. However, Baylor Research Institute investigators gained better insight into LOX-1's role in immune responses through a study recently published in Immunity. Investigators found that the lipoprotein promotes humoral responses, which could allow researchers to design effective vaccines against microbial infections, including influenza viruses and HIV. [More]
Researchers identify new targets for future CLL therapies

Researchers identify new targets for future CLL therapies

Chronic lymphocytic leukemia (CLL) is among the most frequent leukemias affecting adults in Western countries. It usually occurs in older patients, does not cause any symptoms for a long time and is often only discovered by accident. Despite treatment, relapses frequently occur. The immunologists Dr. Kristina Heinig and Dr. Uta Höpken (Max Delbrück Center for Molecular Medicine, MDC, Berlin-Buch) and the hematologist Dr. Armin Rehm (MDC and Charité - Universitätsmedizin Berlin) have now discovered why this is so. [More]
Targeting CXCR4–CXCL12–CXCR7 axis combats mTOR inhibitor resistance in renal cancer

Targeting CXCR4–CXCL12–CXCR7 axis combats mTOR inhibitor resistance in renal cancer

There is considerable crosstalk between the CXCR4–CXCL12–CXCR7 axis and the mammalian target of rapamycin pathway in human renal cell carcinoma, and targeting the axis may overcome drug resistance to mTOR inhibitors, researchers suggest. [More]
Inflammatory shift in long-standing bipolar disorder

Inflammatory shift in long-standing bipolar disorder

Patients with chronic bipolar disorder, but not those with schizophrenia, have a shift towards an M1 rather than an M2 macrophage response, research suggests. [More]
Discovery may lead to new treatments for common autoimmune diseases

Discovery may lead to new treatments for common autoimmune diseases

Researchers at the University of Georgia report in the Journal of Biological Chemistry that an enzyme known as Tumor Progression Locus 2, or Tpl2, plays a key role in directing and regulating several important components of the body's immune system. [More]
ASCO: Biothera to present phase 2 study data on predictive serum biomarker for NSCLC

ASCO: Biothera to present phase 2 study data on predictive serum biomarker for NSCLC

Biothera will present research at the American Society of Clinical Oncology annual meeting linking a potential predictive serum biomarker to the clinical response to Imprime PGG immunotherapy in a recent phase 2 study in non-small cell lung cancer patients. The meeting begins today and runs through June 3 in Chicago. [More]
IL-8 expression predicts lung adenocarcinoma prognosis

IL-8 expression predicts lung adenocarcinoma prognosis

Interleukin -8 expression is associated with a poor lung adenocarcinoma prognosis, say Japanese researchers, especially in patients whose tumours are positive for the KRAS mutation. [More]
Novel molecule prevents symptoms linked with allergen-induced asthma

Novel molecule prevents symptoms linked with allergen-induced asthma

A new study carried out by researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham), the Max Planck Institute for Colloids and Interfaces (Germany), the Free University of Berlin (Germany), UC San Diego, and Shinshu University (Japan) has identified a novel molecule that prevents T-cells from orchestrating asthma brought on by allergens. [More]
Inflammation may accentuate age-related bladder function decline

Inflammation may accentuate age-related bladder function decline

Age-associated biochemical changes in the bladder may accentuate the inflammation associated with overactive bladder, study findings indicate. [More]
Inovio Pharmaceuticals reports total revenue of $2.4 million for first quarter 2014

Inovio Pharmaceuticals reports total revenue of $2.4 million for first quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2014. [More]
Immunoregulatory genes modulate otitis media risk

Immunoregulatory genes modulate otitis media risk

Variation in genes involved in immunity influences children’s susceptibility to developing otitis media, according to research by a US team. [More]
Research grants could improve patients' recovery from athletic and nonathletic injuries

Research grants could improve patients' recovery from athletic and nonathletic injuries

Two orthopedic organizations have presented Beaumont Health System with prestigious, competitive research grants that could improve patients' recovery from both athletic and nonathletic injuries. [More]
Protein expression predicts postop NSCLC recurrence, survival

Protein expression predicts postop NSCLC recurrence, survival

US-based researchers have identified a panel of 12 proteins that may help predict overall survival and the risk of recurrence in patients treated with surgery for non-small-cell lung cancer. [More]
BioLineRx to initiate Phase 1/2 clinical trial on new drug candidate for CML treatment

BioLineRx to initiate Phase 1/2 clinical trial on new drug candidate for CML treatment

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that Prof. Arnon Nagler, Director of the Hematology Division and Bone Marrow Transplantation Center at Sheba Medical Center, Israel, has received final regulatory approval to evaluate BioLineRx's BL-8040 as a treatment for chronic myeloid leukemia (CML) in a Phase 1/2 clinical study. [More]
TFDA approves TaiGen's Taigexyn NDA for treatment of community-acquired bacterial pneumonia

TFDA approves TaiGen's Taigexyn NDA for treatment of community-acquired bacterial pneumonia

TaiGen Biotechnology Company, Limited today announced that the Taiwan Food and Drug Administration has approved the new drug application (NDA) of Taigexyn (nemonoxacin) oral formulation (500 mg) for the treatment of community-acquired bacterial pneumonia (CAP). With this NDA approval, Taiwan is the first region to grant marketing approval to Taigexyn. [More]
Researchers seek to understand causes of premature birth with support from March of Dimes

Researchers seek to understand causes of premature birth with support from March of Dimes

Five researchers seeking to understand the causes of premature birth with the goal of identifying women at risk of preterm labor and developing new treatments to prevent it have been awarded grant support from the March of Dimes. [More]
Researcher to receive AACR- Joseph H. Burchenal Memorial Award for achievement in cancer research

Researcher to receive AACR- Joseph H. Burchenal Memorial Award for achievement in cancer research

John F. DiPersio, M.D., Ph.D., will be recognized with the 19th Annual American Association for Cancer Research-Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research at the AACR Annual Meeting 2014, to be held in San Diego, Calif., April 5-9. [More]
BioLineRx's BL-8040 gets FDA Orphan Drug Designation for stem cell mobilization treatment

BioLineRx's BL-8040 gets FDA Orphan Drug Designation for stem cell mobilization treatment

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received notice from the U.S. Food & Drug Administration confirming an Orphan Drug Designation of BL-8040 as a treatment for stem cell mobilization, in addition to the Orphan Drug Designation previously granted to BL-8040 as a treatment for Acute Myeloid Leukemia. [More]
Inovio Pharmaceuticals unveils new DNA-based cytokine immune activator

Inovio Pharmaceuticals unveils new DNA-based cytokine immune activator

Inovio Pharmaceuticals, Inc. today unveiled that the company has developed a new DNA-based cytokine immune activator, interleukin -33 (IL-33), that in combination with optimized DNA vaccines delivered by electroporation increased the potency and efficacy of the therapeutic response to the DNA vaccines in a preclinical study. [More]
TaiGen, R-Pharm sign exclusive agreement to develop and commercialize nemonoxacin

TaiGen, R-Pharm sign exclusive agreement to develop and commercialize nemonoxacin

TaiGen Biotechnology Company, Limited today announced that they have signed an exclusive agreement with R-Pharm, a leading Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn) in the Russian Federation, Turkey and other members of the Commonwealth Independent States. [More]